Eupraxia Pharmaceuticals: Top 10 Undervalued Growth Stocks on TSX (EPRX)
Eupraxia Pharmaceuticals is now ranked among the top 10 undervalued small cap growth stocks on the Toronto Stock Exchange (TSX).
- A stock is considered undervalued if it trades at a discount to its valuation – a calculation used to determine the intrinsic (true) worth of a company
- Valuation methodology provided by Stockcalc (see below)
- Small, micro and nano group market capitalization (<10B)
Stocks in this category that have grown their revenue significantly in their latest quarterly report. They are held primarily for capital appreciation but do present downside risk. Growth stocks are always of interest to investors as they present upside opportunity. Stocks that are both growing their quarterly revenue and showing as undervalued are of special interest as these two factors are important when looking for prospects.
| Symbol | Name | Close Price ($) | Valuation ($) | Difference | Average Vol (30D) | Market Cap ($M) | Yield (%) | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
| FAF | Fire & Flower Holdings | 0.29 | 0.42 | 0.13 (43.7%) | 13.2 | 0.0 | 0.0 | |
| PMN | ProMIS Neurosciences | 6.24 | 6.47 | 0.23 (3.7%) | 10525 | 53.5 | 0.0 | 0.0 |
| AC | Air Canada | - | - | - (0.0%) | 0.0 | 0.0 | 3.1 | |
| ADCO | Adcore | - | - | - (0.0%) | 0.0 | 0.0 | 0.0 | |
| AEG | Aegis Brands | - | - | - (0.0%) | 0.0 | 0.0 | 0.0 | |
| AOT | Ascot Resources | - | - | - (0.0%) | 0.0 | 0.0 | 0.0 | |
| ARR | Altius Renewable | - | - | - (0.0%) | 0.0 | 0.0 | 0.0 | |
| ASM | Avino Silver & Gold Mines | - | - | - (0.0%) | 0.0 | 0.0 | 74.8 | |
| ATZ | Aritzia | - | - | - (0.0%) | 0.0 | 0.0 | 56.1 | |
| BB | BlackBerry | - | - | - (0.0%) | 0.0 | 0.0 | 0.0 | |
| BKI | Black Iron | - | - | - (0.0%) | 0.0 | 0.0 | 0.0 | |
| BLCO | Bausch & Lomb | - | - | - (0.0%) | 0.0 | 0.0 | 0.0 | |
| BNE | Bonterra Energy | - | - | - (0.0%) | 0.0 | 0.0 | 5.0 | |
| CEF-U | Sprott Physical Gold | - | - | - (0.0%) | 0.0 | 0.0 | 12.0 | |
| CET | Cathedral Energy Services | - | - | - (0.0%) | 0.0 | 0.0 | 11.6 | |
| CFP | Canfor | - | - | - (0.0%) | 0.0 | 0.0 | 0.0 | |
| CPLF | Copperleaf Technologies | - | - | - (0.0%) | 0.0 | 0.0 | 0.0 | |
| CWEB | Charlottes Web Holdings | - | - | - (0.0%) | 0.0 | 0.0 | 0.0 | |
| CXB | Calibre Mining | - | - | - (0.0%) | 0.0 | 0.0 | 10.1 | |
| CYB | Cymbria | - | - | - (0.0%) | 0.0 | 0.0 | 7.5 | |
| E | Enterprise Group | - | - | - (0.0%) | 0.0 | 0.0 | 9.6 | |
| EAGR | East Side Games Grp | - | - | - (0.0%) | 0.0 | 0.0 | 24.8 | |
| ELR | Eastern Platinum | - | - | - (0.0%) | 0.0 | 0.0 | 1.7 | |
| EPRX | Eupraxia Pharmaceuticals | - | - | - (0.0%) | 0.0 | 0.0 | 0.0 | |
| EQX | Equinox Gold | - | - | - (0.0%) | 0.0 | 0.0 | 0.0 |
All data provided as of June 29, 2024.
The list is sorted by stocks with the greatest percentage difference between valuation and price.
Companies included above have not paid a dividend in the last 12-months.
Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with significant unmet medical needs.
Eupraxia Pharmaceuticals is listed under EPRX on the Toronto Stock Exchange.
Stockcalc
StockCalc is a Canadian fintech company specializing in fundamental valuations for North American stocks and ETFs.
Stockcalc valuations (https://www.stockcalc.com/Resources) can help determine if a stock is undervalued. Stockcalc’s Weighted Average Valuation (WAV) is based on a proprietary calculation using model and analyst inputs, including:
- Discounted Cash Flow (DCF)
- Price & Other Comparables
- Multiples
- Adjusted Book Value (ABV)
- Analyst Consensus
Artificial Intelligence at Report on Business
Report on Business scans market data using algorithms to process large quantities of information. The results are specialized reports produced through automation. Ongoing ROB project experiments that leverage artificial intelligence include valuation screens across 14 categories and end-of-day Closing Summary reports for all North American securities.
